Semaglutide Constipation: Why It Happens and How to Manage It

Why Semaglutide Causes Constipation

Semaglutide is a GLP-1 receptor agonist. Activating those receptors slows the rate at which the stomach empties into the small intestine, and the slowdown carries on further along the tract. This is not an unwanted extra. Delayed emptying is a large part of why food stays with you longer and why appetite drops.

Constipation is what that same slowdown looks like once it reaches the colon. The colon's job is to reclaim water from what passes through, and giving it extra time with the same material means it reclaims more. Stool ends up firmer and drier, and that is harder to move. Nausea and constipation are two ends of one mechanism, which is why people often get both and why they do not behave the same way over time.

Why it can outlast nausea

The Wegovy label reports no duration for any gastrointestinal reaction, so what follows is reasoning from the mechanism rather than a measured finding. Nausea has one driver. Constipation has two. On top of the mechanical slowdown, you are eating less, which means less fiber and less bulk entering the gut, and people eating noticeably less usually drink less as well without deciding to. A slower system is being handed a smaller, drier input stream. A 2026 review of nausea and vomiting in GLP-1 based obesity therapies describes nausea as typically easing as people adapt to a dose (Alhazmi and le Roux, PMID 41852477), which sets up the contrast, though the Wegovy label reports no duration data for constipation to compare against.

The gastroparesis boundary

Section 5.6 of the Wegovy prescribing information is titled Severe Gastrointestinal Adverse Reactions, and it ends with a short instruction: Wegovy is not recommended in patients with severe gastroparesis. That sits at the far end of the same mechanism. If gastric motility is already badly impaired, adding a drug that slows it further is a poor trade. The same section reports severe gastrointestinal reactions in 4.1% of adults on Wegovy injection versus 0.9% on placebo, a much narrower category than the 24% constipation figure and not a subset of it. A diagnosed motility disorder or a history of bowel disease belongs in the conversation before you start, not after symptoms appear. The broader semaglutide side effects guide covers the wider picture.

How Common Is Semaglutide Constipation? The Wegovy Label, Split by Dose Pool

The Wegovy label does not report one blended constipation rate. Section 6.1 carries three separate adverse-reaction tables, built from different trial programs in different populations, and each answers a different question. Most published guidance quotes whichever number it found first. Keeping them apart is the whole point of this section.

The 2.4 mg pool, Table 3

This is the figure almost everyone means by "semaglutide constipation." Table 3 pools the placebo-controlled weight-reduction trials in adults with obesity or overweight, comparing the 2.4 mg once-weekly maintenance dose against placebo.

Roughly one in four people reported it, against roughly one in nine on placebo. Constipation is common in the general population, which is why the placebo arm is not zero, and the gap between the two columns is the part attributable to treatment.

Why the 7.2 mg table cannot answer the dose question

Table 4 covers the 7.2 mg maximum dose, drawn from a separate pair of studies in adults with obesity. It is tempting to line its numbers up against Table 3 and read a dose-response curve out of them. That reading does not hold, for a reason printed in the table's own caption: Table 4 lists adverse reactions occurring at 2% or greater and at a greater rate than both the Wegovy 2.4 mg arm and placebo. A reaction only earns a row if it exceeded the 2.4 mg arm. Every row therefore rises with dose by construction. That is a property of the table's filter, not a finding about the drug, and no percentage inside it can establish that constipation worsens at the higher dose.

The comparison across tables fails for a different reason. Table 3 and Table 4 come from different trial programs, with different patient populations and very different group sizes, so the 24% in one and any figure in the other are not two points on a shared line. Reading a decline into that pairing would be as wrong as reading a rise into it.

The practical version: 2.4 mg is the recommended maintenance dose for weight reduction in adults, and 7.2 mg is a maximum the label permits only after at least four weeks of tolerating 2.4 mg and only when further weight reduction is clinically indicated. That 7.2 mg option is scoped to weight reduction in adults. Wegovy's cardiovascular risk-reduction, pediatric and liver-fibrosis indications all stop at 2.4 mg. Constipation is a reasonable thing to weigh when discussing that step with a prescriber, but the label supplies no interpretable number for that difference, since the only figures it offers sit inside a table built by the filter described above.

Managing Semaglutide Constipation: What to Raise With Your Prescriber

None of this is a prescription. It does not replace a conversation with the clinician who put you on the drug. These are the levers clinicians tend to reach for first, in roughly that order.

Fluid intake

Water is the single variable most directly connected to the mechanism. The problem is drier stool, and eating far less tends to cut fluid intake without anyone noticing, because a good share of daily water arrives inside food. Spreading fluid across the day works better than trying to catch up in the evening. This matters twice over. Section 5.5 ties postmarketing reports of acute kidney injury to dehydration from gastrointestinal reactions, naming nausea, vomiting and diarrhea. Constipation is not on that list and is not itself dehydrating. The point is that fluid intake is worth defending across all of them, not that constipation dries you out.

Fiber, increased gradually

Smaller meals mean less fiber by default. Adding it back through vegetables, fruit, oats and legumes gives the colon something to work with. Add it in steps rather than all at once. A large sudden increase in fiber inside a slow gut tends to produce bloating and gas, which is not the outcome anyone is after.

Movement

Regular walking supports gut motility, and it is the easiest of the three to keep going on a week when appetite is low and energy is lower. Consistency does more here than intensity.

Timing around dose steps

The standard escalation runs 0.25 mg, then 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg, with four weeks at each step, and the optional increase to 7.2 mg comes only after at least four weeks of tolerating 2.4 mg. Semaglutide's half-life is about seven days. The Ozempic label, covering semaglutide in type 2 diabetes at 0.5, 1 and 2 mg weekly, states that steady-state exposure is reached after four to five weeks of once-weekly dosing. The Wegovy label reports steady-state concentrations but gives no weeks figure, so carrying four to five weeks across to Wegovy dosing is a reasonable extrapolation rather than something the Wegovy label says. In practice, the weeks right after a step up are when the pattern is still settling. Better to have the fluid and fiber habits already running by then.

Over-the-counter options

Fiber supplements, osmotic laxatives and stool softeners are the categories clinicians commonly discuss when the basics are not enough. This guide names no product and no dose. Which category suits you depends on your medical history, your other medications, and what your bowel pattern actually looks like. Semaglutide's delayed gastric emptying has the potential to affect how oral medications are absorbed, though the label also reports that trials at the 1 mg injection dose found no such effect. Ask the person who prescribed it before starting anything.

Watch: A Physician on Constipation With Semaglutide

Bazgha Khalid, MD, a weight-loss physician, walks through why constipation happens on semaglutide and the practical steps she discusses with patients. The video refers to the drug by its diabetes brand name; the incidence figures in this guide come from the Wegovy label and are not drawn from the video.

When It Is More Than Simple Constipation

Section 6.2 of the Wegovy prescribing information lists adverse reactions reported after approval. Under Gastrointestinal Disorders it names acute pancreatitis and necrotizing pancreatitis, then ileus, intestinal obstruction, and severe constipation including fecal impaction. Postmarketing reports arrive voluntarily from a population of uncertain size, so the label states it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. What they do establish is that these events have been reported, which is enough reason to know the symptoms.

When to Talk to Your Clinician

Short of the red flags above, there is a wide band where constipation is not an emergency but is still worth a call rather than another fortnight of hoping. Raise it if:

• It has not improved after roughly two weeks of consistent fluid, fiber and movement changes.
• It is interfering with work, sleep or how you plan your week.
• You are straining enough to cause bleeding, pain or hemorrhoids.
• You have a history of bowel disease, a motility disorder or previous abdominal surgery.
• Constipation is alternating with diarrhea rather than settling into one pattern.
• You are considering the step up to the 7.2 mg maximum and want the gastrointestinal side of that decision on the table.

Do not stop or change the dose on your own. Constipation is a known and common effect that is usually managed alongside treatment, and a dose change driven by one symptom leaves out the rest of the picture.

Quick-Reference Checklist

Frequently Asked Questions

References

1. Novo Nordisk Pharmaceutical Industries, LP. WEGOVY (semaglutide) injection, for subcutaneous use. Full Prescribing Information, Sections 2.2, 5.5, 5.6, 6.1 (Tables 3 and 4), 6.2, 7.2, 12.3. Revised 6/2026. DailyMed, setid ee06186f-2aa3-4990-a760-757579d8f77b
2. Novo Nordisk A/S. OZEMPIC (semaglutide) injection, for subcutaneous use. Full Prescribing Information, Section 12.3 Pharmacokinetics. DailyMed, setid adec4fd2-6858-4c99-91d4-531f5f2a2d79 (cited only for the steady-state exposure statement, which is scoped to a type 2 diabetes population)
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
4. Alhazmi A, le Roux CW. Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies. Front Endocrinol (Lausanne). 2026. PMID 41852477. PubMed 41852477
5. U.S. Food and Drug Administration. Drugs@FDA product and labeling records for semaglutide products. accessdata.fda.gov

Related Articles